Johnson & Johnson sued by cancer victims alleging 'fraudulent' transfers, bankruptcies [USA TODAY]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: USA TODAY
prevent victims of its "asbestos-contaminated" talcum powder from receiving their day in court and proper compensation. The five individuals who filed the proposed class action suit Wednesday in New Jersey federal court seek to represent anyone who, as of Aug. 11, 2023, either had pending litigation alleging asbestos or other ingredients in Johnson & Johnson talcum powder products caused them to develop ovarian cancer or mesothelioma. The suit stems from Johnson & Johnson's filing for bankruptcy multiple times, and in different states, to resolve tens of thousands of lawsuits claiming the company's talcum baby powder caused cancer. Earlier this month, Johnson & Johnson announced that a third bankruptcy filing of a subsidiary company would allow it to move forward with a $6.475 billion proposed settlement for the victims, reported. A three-month voting period is underway to reach a consensus settlement for current and future victims who claim the baby powder caused ovarian cancer
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson (NYSE: JNJ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $175.00 price target on the stock.MarketBeat
- Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer [Yahoo! Finance]Yahoo! Finance
- Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancerPR Newswire
- Johnson & Johnson's nipocalimab shows promise in Sjögren's disease trial [Yahoo! Finance]Yahoo! Finance
- Let Your Brain Help You Be More Effective At Work [Forbes]Forbes
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 6/6/24 - Form 4
- 6/6/24 - Form 4
- 5/28/24 - Form SD
- JNJ's page on the SEC website